Allopurinol Reduces Mortality in Gout Save
CVD risk is significantly augmented in gout. Choi and coworkers studied this issue using a UK general population database using an incident user cohort study with propensity score matching. Among 5927 allopurinol initiators and 5927 matched comparators, 654 and 718, respectively, died during the follow-up (mean=2.9 years). Allopurinol initiation was associated with a lower risk of all-cause mortality (matched HR 0.89 (95% CI 0.80 to 0.99). When the analysis was limited to those with gout, the corresponding HR was 0.81 (95% CI 0.70 to 0.92).